Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai’s Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese drug maker says it now plans to file the AMPA receptor antagonist in fiscal fourth quarter 2008, not fiscal 2007.

You may also be interested in...



Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010

New studies in neuropathic pain and epilepsy employ doses up to 12mg, compared to 2mg and 4mg doses in Parkinson’s studies.

Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010

New studies in neuropathic pain and epilepsy employ doses up to 12mg, compared to 2mg and 4mg doses in Parkinson’s studies.

Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By Bristol-Myers Squibb Drug

Ixempra already cleared for identical breast cancer indication.

Related Content

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel